Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the submission of a Biologics License Application (BLA) to the U.S.
Derek Archila thinking twice before ready to bet on Teva’s turnaround, but Synergy could bring some upside.
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are diving nearly 15% in Wednesday’s trading session, following the news that competitor Mylan N.V.
A glimpse into why Louise Chen believes Valeant is the better biotech play than Teva down the line.
Here’s a glimpse into this hedge fund guru’s Q2 moves that reeled back in three biotech players.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 …
Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Nuvelution Pharma are officially in collaboration for the development of AUSTEDO (deutetrabenazine) tablets, designed to treat Tourette …
Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.
